{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:03:47Z","timestamp":1794002627315,"version":"4.8.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The Z-drugs are indicated for the short-treatment of insomnia, but they are associated with abuse, dependence and side-effects.\u00a0There are only sparse data about Z-drug prescribing\u00a0in Greece.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We analyzed\u00a0data from the Greek prescription database, considering prescriptions for the available Z-drugs in Greece, i.e.,\u00a0zolpidem and zopiclone, during\u00a0the period from 01.10.2018\u00a0to 01.10.2021 in order to examine the prevalence, monthly number and characteristics of Z-drug prescriptions in Greece.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There were 1,229,842 prescriptions for Z-drugs (zolpidem: 89.7%)\u00a0during the investigated period from 2018 to 2021, which\u00a0corresponded to 156,554 patients (73.1%\u2009\u2265\u200965\u00a0years, 64.5% female). More than half of the patients (65.8%) had more than one prescription with a median number of 8, interquartile range\u00a0IQR [3, 17], prescriptions during the three-year study period. Most patients (76.1%) were prescribed by medical specialties other than psychiatrists and neurologists, despite a considerable frequency of psychiatric comorbidities (53.7%). About half of patients with anxiety\/depression were not prescribed anxiolytics or antidepressants, a practice more frequently observed among medical specialties other than psychiatrists and neurologists. The average\u00a0annual prevalence of\u00a0at least one prescription for Z-drugs in the Greek population during 2019\u20132020 was\u00a0approximately 0.9% (higher in females and older adults). The monthly number of prescriptions was relatively stable with a median\u00a0number of 334.2 IQR [310.4; 351.6] prescriptions per 100,000 persons.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>A considerable number of patients are prescribed Z-drugs in Greece, more often older adults, females and patients with psychiatric comorbidities. The prescribing physicians were in the majority (70%) internists and general practitioners, while psychiatrists (10.9%) and neurologists (6.1%)\u00a0accounted for a smaller proportion. Due to the limitations inherent to medical claims databases, further research is warranted in order to elucidate the potential abuse and misuse of Z-drugs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-023-04793-x","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T10:02:28Z","timestamp":1685095348000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prescribing Z-drugs in Greece: an analysis of the national prescription database from 2018 to 2021"],"prefix":"10.1186","volume":"23","author":[{"given":"Spyridon","family":"Siafis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos N.","family":"Fountoulakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Fragkidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Papazisis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"issue":"9","key":"4793_CR1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","volume":"21","author":"H-U Wittchen","year":"2011","unstructured":"Wittchen H-U, Jacobi F, Rehm J, Gustavsson A, Svensson M, J\u00f6nsson B, Olesen J, Allgulander C, Alonso J, Faravelli C. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655\u201379.","journal-title":"Eur Neuropsychopharmacol"},{"key":"4793_CR2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1186\/1471-2458-10-531","volume":"10","author":"T Paparrigopoulos","year":"2010","unstructured":"Paparrigopoulos T, Tzavara C, Theleritis C, Psarros C, Soldatos C, Tountas Y. Insomnia and its correlates in a representative sample of the Greek population. BMC Public Health. 2010;10:531.","journal-title":"BMC Public Health"},{"key":"4793_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.113076","volume":"289","author":"P Voitsidis","year":"2020","unstructured":"Voitsidis P, Gliatas I, Bairachtari V, Papadopoulou K, Papageorgiou G, Parlapani E, Syngelakis M, Holeva V, Diakogiannis I. Insomnia during the COVID-19 pandemic in a Greek population. Psychiatry Res. 2020;289: 113076.","journal-title":"Psychiatry Res"},{"issue":"6","key":"4793_CR4","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/jsr.12594","volume":"26","author":"D Riemann","year":"2017","unstructured":"Riemann D, Baglioni C, Bassetti C, Bjorvatn B, DolencGroselj L, Ellis JG, Espie CA, Garcia-Borreguero D, Gjerstad M, Gon\u00e7alves M, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26(6):675\u2013700.","journal-title":"J Sleep Res"},{"issue":"10347","key":"4793_CR5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S0140-6736(22)00878-9","volume":"400","author":"F De Crescenzo","year":"2022","unstructured":"De Crescenzo F, D\u2019Al\u00f2 GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N, Kurtulmus A, Tomlinson A, Mitrova Z, Foti F, et al. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet. 2022;400(10347):170\u201384.","journal-title":"Lancet"},{"issue":"4","key":"4793_CR6","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/ijnp\/pyz007","volume":"22","author":"F Schifano","year":"2019","unstructured":"Schifano F, Chiappini S, Corkery JM, Guirguis A. An insight into Z-drug abuse and dependence: an examination of reports to the european medicines agency database of suspected adverse drug reactions. Int J Neuropsychopharmacol. 2019;22(4):270\u20137.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"37","key":"4793_CR7","first-page":"607","volume":"116","author":"S Buth","year":"2019","unstructured":"Buth S, Holzbach R, Martens M-S, Neumann-Runde E, Meiners O, Verthein U. Problematic medication with Benzodiazepines, \u201cZ-drugs\u201d, and opioid analgesics. Dtsch Arztebl Int. 2019;116(37):607\u201314.","journal-title":"Dtsch Arztebl Int"},{"key":"4793_CR8","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2147\/NDT.S290104","volume":"17","author":"S Landolt","year":"2021","unstructured":"Landolt S, Rosemann T, Blozik E, Br\u00fcngger B, Huber CA. Benzodiazepine and Z-drug use in Switzerland: prevalence, prescription patterns and association with adverse healthcare outcomes. Neuropsychiatr Dis Treat. 2021;17:1021\u201334.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"4793_CR9","doi-asserted-by":"publisher","first-page":"e187399","DOI":"10.1001\/jamanetworkopen.2018.7399","volume":"2","author":"SD Agarwal","year":"2019","unstructured":"Agarwal SD, Landon BE. Patterns in outpatient benzodiazepine prescribing in the United States. JAMA Netw Open. 2019;2(1):e187399\u2013e187399.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"4793_CR10","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1111\/bcp.13570","volume":"84","author":"CA Cadogan","year":"2018","unstructured":"Cadogan CA, Ryan C, Cahir C, Bradley CP, Bennett K. Benzodiazepine and Z-drug prescribing in Ireland: analysis of national prescribing trends from 2005 to 2015. Br J Clin Pharmacol. 2018;84(6):1354\u201363.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"4793_CR11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.5665\/sleep.1700","volume":"35","author":"M Calem","year":"2012","unstructured":"Calem M, Bisla J, Begum A, Dewey M, Bebbington PE, Brugha T, Cooper C, Jenkins R, Lindesay J, McManus S. Increased prevalence of insomnia and changes in hypnotics use in England over 15 years: analysis of the 1993, 2000, and 2007 national psychiatric morbidity surveys. Sleep. 2012;35(3):377\u201384.","journal-title":"Sleep"},{"key":"4793_CR12","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3389\/fneur.2020.01012","volume":"11","author":"C Bakirtzis","year":"2020","unstructured":"Bakirtzis C, Grigoriadou E, Boziki MK, Kesidou E, Siafis S, Moysiadis T, Tsakona D, Thireos E, Nikolaidis I, Pourzitaki C, et al. The administrative prevalence of multiple sclerosis in Greece on the basis of a nationwide prescription database. Front Neurol. 2020;11:1012.","journal-title":"Front Neurol"},{"key":"4793_CR13","unstructured":"ELSTAT: Estimated population \/ 2021. https:\/\/www.statistics.gr\/en\/statistics\/-\/publication\/SPO18\/-. In.; 2021."},{"key":"4793_CR14","unstructured":"R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/."},{"issue":"1","key":"4793_CR15","doi-asserted-by":"publisher","first-page":"zsab258","DOI":"10.1093\/sleep\/zsab258","volume":"45","author":"CM Morin","year":"2022","unstructured":"Morin CM, V\u00e9zina-Im LA, Ivers H, Micoulaud-Franchi JA, Philip P, Lamy M, Savard J. Prevalent, incident, and persistent insomnia in a population-based cohort tested before (2018) and during the first-wave of COVID-19 pandemic (2020). Sleep. 2022;45(1):zsab258.","journal-title":"Sleep"},{"issue":"4","key":"4793_CR16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40268-017-0207-7","volume":"17","author":"J Brandt","year":"2017","unstructured":"Brandt J, Leong C. Benzodiazepines and Z-drugs: an updated review of major adverse outcomes reported on in epidemiologic research. Drugs R&D. 2017;17(4):493\u2013507.","journal-title":"Drugs R&D"},{"issue":"6","key":"4793_CR17","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.5664\/jcsm.7172","volume":"14","author":"D Patel","year":"2018","unstructured":"Patel D, Steinberg J, Patel P. Insomnia in the elderly: a review. J Clin Sleep Med. 2018;14(6):1017\u201324.","journal-title":"J Clin Sleep Med"},{"issue":"2","key":"4793_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.12967","volume":"29","author":"C Baglioni","year":"2020","unstructured":"Baglioni C, Altena E, Bjorvatn B, Blom K, Bothelius K, Devoto A, Espie CA, Frase L, Gavriloff D, Tuuliki H, et al. The European academy for cognitive behavioural therapy for insomnia: an initiative of the European insomnia network to promote implementation and dissemination of treatment. J Sleep Res. 2020;29(2): e12967.","journal-title":"J Sleep Res"},{"issue":"10347","key":"4793_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0140-6736(22)01322-8","volume":"400","author":"MT Samara","year":"2022","unstructured":"Samara MT. What is the right drug for insomnia disorder? The Lancet. 2022;400(10347):139\u201341.","journal-title":"The Lancet"},{"issue":"1","key":"4793_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/acps.13201","volume":"142","author":"MT Samara","year":"2020","unstructured":"Samara MT, Huhn M, Chiocchia V, Schneider-Thoma J, Wiegand M, Salanti G, Leucht S. Efficacy, acceptability, and tolerability of all available treatments for insomnia in the elderly: a systematic review and network meta-analysis. Acta Psychiatr Scand. 2020;142(1):6\u201317.","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"4793_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40271-016-0182-z","volume":"10","author":"C Sirdifield","year":"2017","unstructured":"Sirdifield C, Chipchase SY, Owen S, Siriwardena AN. A systematic review and meta-synthesis of patients\u2019 experiences and perceptions of seeking and using benzodiazepines and Z-drugs: towards safer prescribing. Patient - Patient-Centered Outcomes Res. 2017;10(1):1\u201315.","journal-title":"Patient - Patient-Centered Outcomes Res"},{"issue":"1","key":"4793_CR22","doi-asserted-by":"publisher","first-page":"bjgpopen20X1010","DOI":"10.3399\/bjgpopen20X101014","volume":"4","author":"G Gentile","year":"2020","unstructured":"Gentile G, Lapeyre-Mestre M, Micallef J. Combatting the misuse of benzodiazepines and related Z drugs in French general practice: a clinical review. BJGP Open. 2020;4(1):bjgpopen20X101014.","journal-title":"BJGP Open"},{"issue":"2","key":"4793_CR23","doi-asserted-by":"publisher","first-page":"e0228495","DOI":"10.1371\/journal.pone.0228495","volume":"15","author":"P Caillet","year":"2020","unstructured":"Caillet P, Rousselet M, Gerardin M, Jolliet P, Victorri-Vigneau C. Prevalence of zolpidem use in France halved after secure prescription pads implementation in 2017: A SNDS database nested cohort study. PLoS ONE. 2020;15(2):e0228495\u2013e0228495.","journal-title":"PLoS ONE"},{"issue":"8","key":"4793_CR24","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1111\/bcp.14753","volume":"87","author":"M Istvan","year":"2021","unstructured":"Istvan M, Caillet P, Rousselet M, Guerlais M, Laforgue E-J, G\u00e9rardin M, Jolliet P, Feuillet F, Victorri-Vigneau C. Change in the regulatory framework for zolpidem: What is the impact on the landscape of the prescription of sedative medications? The French national ZORRO study. Br J Clin Pharmacol. 2021;87(8):3310\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"4793_CR25","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.3390\/jcm11082176","volume":"11","author":"EJ Laforgue","year":"2022","unstructured":"Laforgue EJ, Istvan M, Schreck B, Mainguy M, Jolliet P, Grall-Bronnec M, Victorri-Vigneau C. Perception of the regulatory change for Zolpidem prescription by French general practitioners and its relation to prescription behavior. J Clin Med. 2022;11(8):2176.","journal-title":"J Clin Med"},{"key":"4793_CR26","unstructured":"Food and Drug Administration Drug Safety Communication. Risk of next-day impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edular, and Zolpimist). UCM 335007. January 10, 2013 Research"},{"issue":"3","key":"4793_CR27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/JCP.0000000000001026","volume":"39","author":"DJ Greenblatt","year":"2019","unstructured":"Greenblatt DJ, Harmatz JS, Roth T. Zolpidem and gender: are women really at risk? J Clin Psychopharmacol. 2019;39(3):189\u201399.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"4793_CR28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1177\/1362361312467709","volume":"18","author":"JP Burke","year":"2014","unstructured":"Burke JP, Jain A, Yang W, Kelly JP, Kaiser M, Becker L, Lawer L, Newschaffer CJ. Does a claims diagnosis of autism mean a true case? Autism. 2014;18(3):321\u201330.","journal-title":"Autism"},{"issue":"4","key":"4793_CR29","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/1475-6773.00164","volume":"38","author":"CM Spettell","year":"2003","unstructured":"Spettell CM, Wall TC, Allison J, Calhoun J, Kobylinski R, Fargason R, Kiefe CI. Identifying physician-recognized depression from administrative data: consequences for quality measurement. Health Serv Res. 2003;38(4):1081\u2013102.","journal-title":"Health Serv Res"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-023-04793-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-023-04793-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-023-04793-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T10:04:31Z","timestamp":1685095471000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-023-04793-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4793"],"URL":"https:\/\/doi.org\/10.1186\/s12888-023-04793-x","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,26]]},"assertion":[{"value":"3 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was an analysis of anonymized data from the Greek nationwide prescription registry database. The Greek nationwide prescription registry database runs under surveillance of the Greek e-Government Center for Social Security Services (IDIKA S.A.) on behalf of the Greek Ministry of Health. The study was reviewed and approved on 21.09.2021 by the Data Protection Office of the Greek Ministry of Health. Therefore, access to the anonymized data was permitted by the Greek Ministry of Health and informed consent to participate was accordingly not applicable. All methods were carried in accordance with relevant guidelines and regulations in the Declaration of Helsinki, whenever applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. Anonymized prescription data were requested and provided for this analysis by the Greek e-Government Center for Social Security Services (IDIKA S.A.) and the Greek Ministry of Health.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KNF has received grants and served as consultant, advisor or CME speaker for the following entities: AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Ferrer, Gedeon Richter, Janssen, Lundbeck, Otsuka, Recordatti, Angellini, Pfizer, the Pfizer Foundation, Sanofi-Aventis, Servier, Shire and others. GP, VF and SS have none to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"370"}}